

Date: November 09, 2020

To Bombay Stock Exchange Limited, P.J. Towers, Dalal Street, Mumbai – 400001

Subject: Press Release

Reference: Regulation 30 read with Schedule III of (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Scrip Code No. 540654

Dear Sir/Madam,

Please find enclosed herewith the Press Release issued by the Company, in regards to briefs of the Financial Result for the quarter and the half- year ended 30th September,2020.

Kindly take note of the same.

FOR GLOBALSPACE TECHNOLOGIES LIMITED

Swati Arora
Company Secretary & Compliance Officer
Memb No.: A44529

Enclosed: Press Release

GIES LIMITED CIN: L64201MH2010PLC211219

Formerly known as 'GlobalSpace Technologies Private Limited' Formerly known as 'GlobalSpace Tech Private Limited'

Regd. Off: Office No. 605, 6th Floor, Rupa Solitiare Building, Millennium Business Park, Mahape, Navi Mumbai 400710 Tel.: 022-49452000 | Email: info@globalspace.in | Website: www.globalspace.in

GlobalSpace Technologies posts results for the quarter ended September 2020

EARNING SYNOPSIS:

On Consolidated basis for the Q2 FY2020-21,

PAT: INR 22.67 Mn (grew by 7% on y-o-y basis)

Revenues: INR 68.97 Mn (jumped by 76% on y-o-y basis)

EBITDA: INR 36.37 Mn (up by 22% on y-o-y basis)

❖ EBITDA and PAT margins stood at 53% and 33% respectively.

EdTech and HealthTech is witnessing significant traction which is likely to drive the performance going forward as well.

Mumbai, November 9, 2020: GlobalSpace Technologies Limited, one of the leading HealthTech and EduTech digital platform provider, today announced robust results for the second quarter ended on September 30, 2020.

Quarterly Comparisons:

On a consolidated basis, total revenue in the second quarter stood at INR 68.97 Mn, 7% higher than INR 64.41 Mn in the same quarter last year. EBITDA was at INR 36.37 Mn, up by 22.9% YoY. EBITDA margin stood at 53%, up by 678 bps YoY. Profit after tax (PAT) grew by 76% to INR 22.67 Mn in Q2FY21 as against INR 12.87 Mn in Q2FY20 with the margin of 33%.

Half-yearly Comparisons:

On a consolidated basis, the Company has achieved six-month revenue of INR 128.59 Mn which is an increase of 12% from the same period last year, of INR 114.72 Mn. EBIDTA amounted to INR 71.2 Mn in H1FY2021 as against INR 32.37 Mn in H1FY2020 with margins of 55%. Profit after tax (PAT) registered an impressive growth of 561% to INR 43.32 Mn in H1FY21 from INR 6.55 Mn in H1FY20 with the margin of 33%.

Commenting on the Company's performance for Q2FY21, Mr. Krishna Singh, Founder & CMD, "This has been a very strong quarter for us where we have managed to achieve significant improvement in revenue and profitability. The growth in profitability is as a result of lower product development cost which were there in the earlier years. We have achieved a consolidated net profit of INR 22.67 Mn for this period and have posted 76% y-o-y growth. We have achieved success faster than that of predicted in both the verticals due to the pandemic situation. Being fully compliant with the guidelines of Government of India, DocExa has been adopted by many Doctors across medical fraternity. At the end of second quarter of fiscal 2021, DocExa has 56,021 Doctors registration. We feel very proud to see notable achievement. Moreover, we have seen a major rise in demand for STEAM learning in Indian markets considering the recently announced 'National Educational Policy' by Government of India. We are already established in India and have also forayed in International market which will help us significantly to increase our presence.'

He further added, 'Within this period of epidemic, the platform has gained significant response in online consultation. The traditional belief has been changed and that led to a greater adoption. The presumption of Doctors that nothing can replace the percussion and stethoscope has been compromised amid this prevailing pandemic across the Globe. Moreover, strategic association with MediApp has enhanced the viability of DocExa platform. This has helped in connecting the Doctor network of DocExa with MediApp's network of over 43000 Pharmacies. The company's edge in both the verticals is likely to be the major growth driver for the company in coming years. During the quarter, Makebot contributed to the revenues from international markets as well, which we expect to be one of the major contributors to our future growth. We remain confident on the long-term prospects of the Company.'

Major Development during this quarter ended on September 2020:

During this quarter, the company has taken significant steps into both the verticals. EdTech:

- Launched its Experiential Educational program including it's "m tiny" Robot through its EdTech subsidiary MAKEBOT, which provides learning experience with 1st of its kind truly integrated hardware and software platform to the children of grade 4-12.
- Makebot has expanded into international geographies in Asia-Pacific & Middle East regions for its STEAM certification programs:
 - Makebot has signed MoUs with 7 established partners in countries like Malaysia (2), Singapore (1), Indonesia (1), Australia (1), New Zealand (1) and Dubai (1).

HealthTech:

- Healthtech platform DocExa has seen increased acceptance across medical fraternity.
- GlobalSpace has made strategic partnership with CCI (Chest Council of India) as well as FOGSI (Federation of Obstetric and Gynaecological Societies of India) to increase their customer reach. With these alliances, DocExa has more category wise specialists' doctors for consulting under its banner.

Rs Million	Q2FY2021	Q2FY2019	% YoY	H1FY2021	H1FY2020	% YoY	FY2020	FY2019	% YoY
Total Revenue	68.97	64.41	7	128.59	114.72	12	259.22	155.12	67
EBITDA	36.37	29.59	22	71.2	32.37	119	67.13	65.01	3
EBITDA Margin (%)	53	46		55	28		25	42	
PAT	22.67	12.87	76	43.32	6.55	561	29.76	12.15	145
PAT Margin (%)	33	20		34	6		11	8	
EPS	1.98	1.12		3.78	2.80		2.49	1.06	

About GlobalSpace Technologies Limited:

GlobalSpace Technologies is a Digital, Mobility, Analytics, AI & Cloud technology Company providing integrated Healthtech platforms to major stakeholders of Healthcare domain. GSTL's software product platforms and solutions enable large and medium enterprises embrace mobility & digital technology for their business enhancement. In addition to Pharma, GlobalSpace has been pioneer in creating solutions for Doctors & Channel to create a 360-degree digital healthcare ecosystem.

Apart from Health Tech, Globalspace is doing some path breaking innovation in Edutech industry with its subsidiary Makebot. Makebot is already India's leading STEAM education platform with more than 1200 School using its platform to impart STEAM learning to its students.

About Makebot Robotic Solutions Private Limited:

Makebot, founded in 2018, is a leading STEAM Education provider using coding on robotics, AI and machine learning and offers STEAM certification programs & International Olympiad for students through its online platform. Makebot STEAM programs are designed to induct 21st century skills in students with heathy competition-based learning methodology and through edutainment. So far, Makebot has over 1,45,000 students and 1200+ schools subscribed to its online certification program on STEAM and the numbers are growing exponentially especially after Post-COVID and launch of new education policy to incorporate STEAM and coding in curriculum.

Reference websites

www.docexa.com

www.makebot.in

www.globalspace.in

For further Information kindly get in touch at:

info@globalspace.in